A Randomized, Single Center, Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of Pandemic Virus Vaccine, AdimrSC-2f (SARS-CoV-2), in Healthy Volunteers
Latest Information Update: 25 May 2022
Price :
$35 *
At a glance
- Drugs AdimrSC-2f (Primary) ; Adjuvants
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Adimmune Corporation
- 23 May 2022 Status changed from active, no longer recruiting to completed.
- 14 Oct 2021 Planned End Date changed from 31 Jul 2021 to 31 Oct 2021.
- 14 Oct 2021 Status changed from recruiting to active, no longer recruiting.